Healthcare
Equillium, Inc.(EQ)
Live Price
Offline$2.81
+0.00% today
1Y Change
+733.33%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $70.00M
- Revenue Growth
- -99.7%
- EPS Growth
- -69.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Equillium, Inc. (EQ) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $2.81 and up 733.3% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -99.7%, EPS growth of -69.6%, a dividend yield of 0.0%. What stands out right now is revenue -99.7%, EPS -69.6%, free cash flow -19.3% with operating margin 0.0% and ROIC -83.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-99.7% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -99.7% and EPS is at -69.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +12.1% | -10.8% | +21.6% |
2026 Mar 25, 2026 | +42.9% | +0.0% | -1.0% | +5.3% |
2025 Nov 13, 2025 | +57.1% | +23.8% | +20.2% | +52.4% |
Benchmark Edge
EQ vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EQ
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EQ Max Drawdown
-57.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EQ and SPY.
Company Overview
Equillium, Inc.
NASDAQ Global Market
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
- Leadership
- Bruce D. Steel
- IPO Date
- Oct 12, 2018
- Employees
- 35
- Street Address
- 2223 Avenida De La Playa
- Mailing
- La Jolla, CA, 92037
- Region
- La Jolla, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 412 5302
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 6.7
Growth
- Revenue
- -99.7%
- EPS
- -69.6%
- Free Cash Flow
- -19.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -119.2%
- ROIC
- -83.3%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 10.32
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.